1
|
Brankiewicz W, Kalathiya U, Padariya M, Węgrzyn K, Prusinowski M, Zebrowska J, Zylicz-Stachula A, Skowron P, Drab M, Szajewski M, Ciesielski M, Gawrońska M, Kallingal A, Makowski M, Bagiński M. Modified Peptide Molecules As Potential Modulators of Shelterin Protein Functions; TRF1. Chemistry 2023; 29:e202300970. [PMID: 37332024 DOI: 10.1002/chem.202300970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 06/02/2023] [Accepted: 06/13/2023] [Indexed: 06/20/2023]
Abstract
In this work, we present studies on relatively new and still not well-explored potential anticancer targets which are shelterin proteins, in particular the TRF1 protein can be blocked by in silico designed "peptidomimetic" molecules. TRF1 interacts directly with the TIN2 protein, and this protein-protein interaction is crucial for the proper functioning of telomere, which could be blocked by our novel modified peptide molecules. Our chemotherapeutic approach is based on assumption that modulation of TRF1-TIN2 interaction may be more harmful for cancer cells as cancer telomeres are more fragile than in normal cells. We have shown in vitro within SPR experiments that our modified peptide PEP1 molecule interacts with TRF1, presumably at the site originally occupied by the TIN2 protein. Disturbance of the shelterin complex by studied molecule may not in short term lead to cytotoxic effects, however blocking TRF1-TIN2 resulted in cellular senescence in cellular breast cancer lines used as a cancer model. Thus, our compounds appeared useful as starting model compounds for precise blockage of TRF proteins.
Collapse
Affiliation(s)
- Wioletta Brankiewicz
- Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Narutowicza St 11/12, 80-233, Gdansk, Poland
| | - Umesh Kalathiya
- International Centre for Cancer Vaccine Science, University of Gdansk, ul. Kładki 24, 80-822, Gdańsk, Poland
| | - Monikaben Padariya
- International Centre for Cancer Vaccine Science, University of Gdansk, ul. Kładki 24, 80-822, Gdańsk, Poland
| | - Katarzyna Węgrzyn
- Intercollegiate Faculty of Biotechnology, University of Gdansk, Abrahama 58, 80-307, Gdansk, Poland
| | - Maciej Prusinowski
- Faculty of Chemistry, University of Gdansk, Wita Stwosza 63, 80-308, Gdansk, Poland
| | - Joanna Zebrowska
- Faculty of Chemistry, University of Gdansk, Wita Stwosza 63, 80-308, Gdansk, Poland
| | | | - Piotr Skowron
- Faculty of Chemistry, University of Gdansk, Wita Stwosza 63, 80-308, Gdansk, Poland
| | - Marek Drab
- Unit of Nanostructural Bio-Interactions, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Weigla-Street, 53-114, Wrocław, Poland
| | - Mariusz Szajewski
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia, Poland
- Division of Propaedeutics of Oncology, Medical University of Gdańsk, Gdańsk, Poland
| | - Maciej Ciesielski
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia, Poland
- Division of Propaedeutics of Oncology, Medical University of Gdańsk, Gdańsk, Poland
| | - Małgorzata Gawrońska
- Faculty of Chemistry, University of Gdansk, Wita Stwosza 63, 80-308, Gdansk, Poland
| | - Anoop Kallingal
- Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Narutowicza St 11/12, 80-233, Gdansk, Poland
| | - Mariusz Makowski
- Faculty of Chemistry, University of Gdansk, Wita Stwosza 63, 80-308, Gdansk, Poland
| | - Maciej Bagiński
- Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Narutowicza St 11/12, 80-233, Gdansk, Poland
| |
Collapse
|
2
|
Dratwa M, Wysoczanska B, Brankiewicz W, Stachowicz-Suhs M, Wietrzyk J, Matkowski R, Ekiert M, Szelachowska J, Maciejczyk A, Szajewski M, Baginski M, Bogunia-Kubik K. Relationship between Telomere Length, TERT Genetic Variability and TERT, TP53, SP1, MYC Gene Co-Expression in the Clinicopathological Profile of Breast Cancer. Int J Mol Sci 2022; 23:5164. [PMID: 35563554 PMCID: PMC9102200 DOI: 10.3390/ijms23095164] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 04/15/2022] [Accepted: 05/04/2022] [Indexed: 12/11/2022] Open
Abstract
The molecular mechanisms of telomerase reverse transcriptase (TERT) upregulation in breast cancer (BC) are complex. We compared genetic variability within TERT and telomere length with the clinical data of patients with BC. Additionally, we assessed the expression of the TERT, MYC, TP53 and SP1 genes in BC patients and in BC organoids (3D cell cultures obtained from breast cancer tissues). We observed the same correlation in the blood of BC patients and in BC organoids between the expression of TERT and TP53. Only in BC patients was a correlation found between the expression of the TERT and MYC genes and between TP53 and MYC. We found associations between TERT genotypes (rs2735940 and rs10069690) and TP53 expression and telomere length. BC patients with the TT genotype rs2735940 have a shorter telomere length, but patients with A allele rs10069690 have a longer telomere length. BC patients with a short allele VNTR-MNS16A showed higher expression of the SP1 and had a longer telomere. Our results bring new insight into the regulation of TERT, MYC, TP53 and SP1 gene expression related to TERT genetic variability and telomere length. Our study also showed for the first time a similar relationship in the expression of the above genes in BC patients and in BC organoids. These findings suggest that TERT genetic variability, expression and telomere length might be useful biomarkers for BC, but their prognostic value may vary depending on the clinical parameters of BC patients and tumor aggressiveness.
Collapse
Affiliation(s)
- Marta Dratwa
- Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland;
| | - Barbara Wysoczanska
- Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland;
| | - Wioletta Brankiewicz
- Department of Pharmaceutical Technology and Biochemistry Faculty of Chemistry, Gdansk University of Technology, 80-233 Gdansk, Poland; (W.B.); (M.B.)
| | - Martyna Stachowicz-Suhs
- Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland; (M.S.-S.); (J.W.)
| | - Joanna Wietrzyk
- Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland; (M.S.-S.); (J.W.)
| | - Rafał Matkowski
- Breast Unit, Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland; (R.M.); (M.E.); (J.S.); (A.M.)
- Department of Oncology, Wroclaw Medical University, 53-413 Wroclaw, Poland
| | - Marcin Ekiert
- Breast Unit, Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland; (R.M.); (M.E.); (J.S.); (A.M.)
- Department of Oncology, Wroclaw Medical University, 53-413 Wroclaw, Poland
| | - Jolanta Szelachowska
- Breast Unit, Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland; (R.M.); (M.E.); (J.S.); (A.M.)
- Department of Oncology, Wroclaw Medical University, 53-413 Wroclaw, Poland
| | - Adam Maciejczyk
- Breast Unit, Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland; (R.M.); (M.E.); (J.S.); (A.M.)
- Department of Oncology, Wroclaw Medical University, 53-413 Wroclaw, Poland
| | - Mariusz Szajewski
- Department of Oncological Surgery, Gdynia Oncology Centre, 81-519 Gdynia, Poland;
- Division of Propaedeutics of Oncology, Medical University of Gdansk, 80-210 Gdansk, Poland
| | - Maciej Baginski
- Department of Pharmaceutical Technology and Biochemistry Faculty of Chemistry, Gdansk University of Technology, 80-233 Gdansk, Poland; (W.B.); (M.B.)
| | - Katarzyna Bogunia-Kubik
- Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland;
| |
Collapse
|
3
|
Madej‑mierzwa A, Szajewski M, Kruszewski W. Comparison of different lymph node staging systems for predicting prognosis in patients with colon cancer who have undergone surgical resection. Oncol Lett 2022; 23:176. [DOI: 10.3892/ol.2022.13296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2022] [Accepted: 03/17/2022] [Indexed: 11/06/2022] Open
Affiliation(s)
- Anna Madej‑mierzwa
- Department of Oncological Surgery, Gdynia Centre of Oncology, Pomeranian Hospitals, Gdynia 81‑519, Poland
| | - Mariusz Szajewski
- Department of Oncological Surgery, Gdynia Centre of Oncology, Pomeranian Hospitals, Gdynia 81‑519, Poland
| | - Wiesław Kruszewski
- Department of Oncological Surgery, Gdynia Centre of Oncology, Pomeranian Hospitals, Gdynia 81‑519, Poland
| |
Collapse
|
4
|
Szefel J, Ślebioda T, Walczak J, Kruszewski WJ, Szajewski M, Ciesielski M, Stanisławowski M, Buczek T, Małgorzewicz S, Owczarzak A, Aleksandrowicz-Wrona E, Krzykowski G. The effect of l-arginine supplementation and surgical trauma on the frequency of myeloid-derived suppressor cells and T lymphocytes in tumour and blood of colorectal cancer patients. Adv Med Sci 2022; 67:66-78. [PMID: 34995935 DOI: 10.1016/j.advms.2021.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 11/22/2021] [Accepted: 12/27/2021] [Indexed: 12/22/2022]
Abstract
PURPOSE l-arginine (L-arg) deficiency causes immunosuppression, but it is unknown if L-arg supplementation in colorectal cancer (CRC) patients restores immune system activity. Our objective was to investigate the effect of L-arg supplementation on the frequency of monocytic (M) and polymorphonuclear (PNM) myeloid-derived suppressor cells (M-MDSCs and PMN-MDSCs, respectively). METHODS We enrolled 65 CRC patients (34 males, 31 females) aged 69 ± 10 years into a prospective, randomised, double-blind study. Twenty-eight patients received L-arg and 37 received placebo for 9 days at a dose of 10 g/day. The frequency changes in MDSC, CD4+ cells and the concentration of C-reactive protein (CRP) were assessed before supplementation with L-arg (test 1), after 9 days of supplementation (test 2), and after surgery on day 11 (test 3). RESULTS The frequency of M-MDSC in the tumours of patients receiving L-arg supplementation was higher than in placebo-treated patients, as was the frequency of PMN-MDSC and M-MDSC in the mucosa. CRP concentration in the serum of placebo-treated patients in test 2 was higher than in test 1, and the concentration in the serum of patients with L-arg supplementation in test 2 was lower than in test 1. Moreover, the expression pattern of the argininosuccinate synthase 1 (ASS1) suggests that CRC is not auxotrophic for L-arg. CONCLUSIONS The results of this study do not support the hypothesis that L-arg supplementation in CRC patients can reduce immunosuppression by decreasing the frequency of suppressor cells and increasing the frequency of effector CD4+ T cells.
Collapse
Affiliation(s)
- Jarosław Szefel
- Division of Oncological Propedeutics, Faculty of Health Sciences, Medical University of Gdansk, Gdynia, Poland.
| | - Tomasz Ślebioda
- Department of Histology, Medical University of Gdansk, Gdansk, Poland
| | - Jakub Walczak
- Department of Surgical Oncology, Gdynia Oncology Centre, Maritime Polish Red Cross Memorial Hospital, Gdynia, Poland
| | - Wiesław Janusz Kruszewski
- Division of Oncological Propedeutics, Faculty of Health Sciences, Medical University of Gdansk, Gdynia, Poland; Department of Surgical Oncology, Gdynia Oncology Centre, Maritime Polish Red Cross Memorial Hospital, Gdynia, Poland
| | - Mariusz Szajewski
- Division of Oncological Propedeutics, Faculty of Health Sciences, Medical University of Gdansk, Gdynia, Poland; Department of Surgical Oncology, Gdynia Oncology Centre, Maritime Polish Red Cross Memorial Hospital, Gdynia, Poland
| | - Maciej Ciesielski
- Division of Oncological Propedeutics, Faculty of Health Sciences, Medical University of Gdansk, Gdynia, Poland; Department of Surgical Oncology, Gdynia Oncology Centre, Maritime Polish Red Cross Memorial Hospital, Gdynia, Poland
| | | | - Tomasz Buczek
- Division of Oncological Propedeutics, Faculty of Health Sciences, Medical University of Gdansk, Gdynia, Poland; Department of Surgical Oncology, Gdynia Oncology Centre, Maritime Polish Red Cross Memorial Hospital, Gdynia, Poland
| | - Sylwia Małgorzewicz
- Department of Clinical Nutrition, Medical University of Gdansk, Gdansk, Poland
| | - Anna Owczarzak
- Department of Clinical Nutrition, Medical University of Gdansk, Gdansk, Poland
| | | | | |
Collapse
|
5
|
Kruszewski WJ, Szajewski M, Ciesielski M, Buczek T, Kawecki K, Walczak J. Level of inferior mesenteric artery ligation does not affect rectal cancer treatment outcomes despite better cancer-specific survival after low ligation-randomized trial results. Colorectal Dis 2021; 23:2575-2583. [PMID: 34251082 DOI: 10.1111/codi.15798] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Revised: 06/20/2021] [Accepted: 06/22/2021] [Indexed: 12/14/2022]
Abstract
AIM In rectal cancer surgery, the problem about which of the mesenteric artery ligation variants (high or low) is more beneficial to the patient remains unsolved. Recent meta-analyses suggest that the risk of surgical complications is similar for both ligation variants. The main objective was to compare the survival time in both groups with a minimum 48 months' follow-up. Secondary objectives were comparison of the number of harvested lymph nodes, the complication rate and other selected data related to the surgery. METHOD This was a randomized, single-centre, unblinded clinical trial of adult patients (n = 130) with cT1-3M0/ycT0-3M0 rectal and rectosigmoid junction adenocarcinoma undergoing radical open surgery. The intervention level was inferior mesenteric artery ligation. RESULTS The mean and median survival in the whole group was 45 months, while in the survivor group it was 83 and 82 months. The survival for 1-5 years, overall survival and disease-free survival were similar in both groups. The cancer-specific survival time was longer in the low inferior mesenteric artery ligation group (P = 0.005 for all and P = 0.02 for pTNM Stage III patients) There were no differences in the incidence of anastomotic leakage and overall morbidity. The median number of lymph nodes located at the root of the inferior mesenteric artery was 1; the mean was 1.7. They were not metastatic in any case. The median total number of harvested nodes was similar in both groups. CONCLUSIONS In radically treated adenocarcinoma of the rectum and the rectosigmoid junction, the level of inferior mesenteric artery ligation below the left colic artery branch provides similar treatment results to inferior mesenteric artery ligation just below its branching from the aorta in relation to overall and disease-free survival, and the risk of complications. Low inferior mesenteric artery ligation results in better cancer-specific survival. The risk of metastases at the mesenteric nodes is negligible.
Collapse
Affiliation(s)
- Wiesław Janusz Kruszewski
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia, Poland.,Division of Propaedeutics of Oncology, Medical University of Gdańsk, Gdansk, Poland
| | - Mariusz Szajewski
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia, Poland.,Division of Propaedeutics of Oncology, Medical University of Gdańsk, Gdansk, Poland
| | - Maciej Ciesielski
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia, Poland.,Division of Propaedeutics of Oncology, Medical University of Gdańsk, Gdansk, Poland
| | - Tomasz Buczek
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia, Poland.,Division of Propaedeutics of Oncology, Medical University of Gdańsk, Gdansk, Poland
| | - Krzysztof Kawecki
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia, Poland
| | - Jakub Walczak
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia, Poland
| |
Collapse
|
6
|
Ciesielski M, Szajewski M, Walczak J, Pęksa R, Lenckowski R, Supeł M, Zieliński J, Kruszewski WJ. Impact of chromosome 17 centromere copy number increase on patient survival and human epidermal growth factor receptor 2 expression in gastric adenocarcinoma. Oncol Lett 2020; 21:142. [PMID: 33552261 PMCID: PMC7798021 DOI: 10.3892/ol.2020.12403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Accepted: 11/16/2020] [Indexed: 12/24/2022] Open
Abstract
The accurate evaluation of human epidermal growth factor receptor 2 (HER2) status is essential for the appropriate use of targeted therapies. An increased number of chromosome 17 centromere enumeration probe (CEP17) signals may underrate fluorescence in situ hybridization (FISH) outcomes, resulting in false-negative or a false-equivocal HER2 status assessment. The aim of the present study was to assess the frequency of CEP17 copy number increase (CNI), its effects on HER2 protein expression (and the subsequent effects on tumor cells), and the survival outcomes of patients with gastric cancer. Archival primary tumor samples from 244 patients that underwent gastric resection for adenocarcinoma were retrieved for both HER2 protein expression analysis (using immunochemistry) and HER2 gene amplification (using FISH). The associations between HER2 status, CEP17 CNI and multiple clinicopathological parameters (including survival outcome), were assessed. The relationship between CEP17 CNI and HER2 protein upregulation was also investigated. CEP17 CNI was detected in 17.2% of cases, and a strong association between CEP17 CNI and HER2 upregulation was revealed. The impact of CEP17 CNI on survival did not reach statistical significance. Consequently, CEP17 CNI was discovered to be strongly associated with HER2 upregulation in tumor cells, which may characterize a critical issue in HER2 testing. Therefore, the eligibility for HER2-targeted agents in CEP17 CNI-positive patients warrants further recognition.
Collapse
Affiliation(s)
- Maciej Ciesielski
- Department of Oncological Surgery, Gdynia Centre of Oncology, Pomeranian Hospitals, Gdynia, Pomeranian Voivodship 81-519, Poland.,Division of Propedeutics of Oncology, Medical University of Gdańsk, Gdańsk, Pomeranian Voivodship 80-210, Poland
| | - Mariusz Szajewski
- Department of Oncological Surgery, Gdynia Centre of Oncology, Pomeranian Hospitals, Gdynia, Pomeranian Voivodship 81-519, Poland.,Division of Propedeutics of Oncology, Medical University of Gdańsk, Gdańsk, Pomeranian Voivodship 80-210, Poland
| | - Jakub Walczak
- Department of Oncological Surgery, Gdynia Centre of Oncology, Pomeranian Hospitals, Gdynia, Pomeranian Voivodship 81-519, Poland
| | - Rafał Pęksa
- Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Pomeranian Voivodship 80-210, Poland
| | - Radosław Lenckowski
- Department of Pathomorphology, Gdynia Centre of Oncology, Pomeranian Hospitals, Gdynia, Pomeranian Voivodship 81-519, Poland
| | - Małgorzata Supeł
- Department of Pathomorphology, Gdynia Centre of Oncology, Pomeranian Hospitals, Gdynia, Pomeranian Voivodship 81-519, Poland
| | - Jacek Zieliński
- Department of Oncological Surgery, Medical University of Gdańsk, Gdańsk, Pomeranian Voivodship 80-210, Poland
| | - Wiesław Janusz Kruszewski
- Department of Oncological Surgery, Gdynia Centre of Oncology, Pomeranian Hospitals, Gdynia, Pomeranian Voivodship 81-519, Poland.,Division of Propedeutics of Oncology, Medical University of Gdańsk, Gdańsk, Pomeranian Voivodship 80-210, Poland
| |
Collapse
|
7
|
Stukan M, Alcazar JL, Gębicki J, Epstein E, Liro M, Sufliarska A, Szubert S, Guerriero S, Braicu EI, Szajewski M, Pietrzak-Stukan M, Fischerova D. Ultrasound and Clinical Preoperative Characteristics for Discrimination Between Ovarian Metastatic Colorectal Cancer and Primary Ovarian Cancer: A Case-Control Study. Diagnostics (Basel) 2019; 9:E210. [PMID: 31805677 PMCID: PMC6963303 DOI: 10.3390/diagnostics9040210] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2019] [Revised: 11/22/2019] [Accepted: 11/29/2019] [Indexed: 11/17/2022] Open
Abstract
The aim of this study was to describe the clinical and sonographic features of ovarian metastases originating from colorectal cancer (mCRC), and to discriminate mCRC from primary ovarian cancer (OC). We conducted a multi-institutional, retrospective study of consecutive patients with ovarian mCRC who had undergone ultrasound examination using the International Ovarian Tumor Analysis (IOTA) terminology, with the addition of evaluating signs of necrosis and abdominal staging. A control group included patients with primary OC. Clinical and ultrasound data, subjective assessment (SA), and an assessment of different neoplasias in the adnexa (ADNEX) model were evaluated. Fisher's exact and Student's t-tests, the area under the receiver-operating characteristic curve (AUC), and classification and regression trees (CART) were used to conduct statistical analyses. In total, 162 patients (81 with OC and 81 with ovarian mCRC) were included. None of the patients with OC had undergone chemotherapy for CRC in the past, compared with 40% of patients with ovarian mCRC (p < 0.001). The ovarian mCRC tumors were significantly larger, a necrosis sign was more frequently present, and tumors had an irregular wall or were fixed less frequently; ascites, omental cake, and carcinomatosis were less common in mCRC than in primary OC. In a subgroup of patients with ovarian mCRC who had not undergone treatment for CRC in anamnesis, tumors were larger, and had fewer papillations and more locules compared with primary OC. The highest AUC for the discrimination of ovarian mCRC from primary OC was for CART (0.768), followed by SA (0.735) and ADNEX calculated with CA-125 (0.680). Ovarian mCRC and primary OC can be distinguished based on patient anamnesis, ultrasound pattern recognition, a proposed decision tree model, and an ADNEX model with CA-125 levels.
Collapse
Affiliation(s)
- Maciej Stukan
- Department of Gynecologic Oncology, Gdynia Oncology Center, Pomeranian Hospitals, 81519 Gdynia, Poland
| | - Juan Luis Alcazar
- Department of Obstetrics and Gynecology, Clínica Universidad de Navarra, 31008 Pamplona, Spain
| | - Jacek Gębicki
- Department of Process Engineering and Chemical Technology, Faculty of Chemistry, Gdańsk University of Technology, 80233 Gdańsk, Poland
| | - Elizabeth Epstein
- Department of Clinical Science and Education, Karolinska Institutet and Department of Obstetrics and Gynecology Södersjukhuset, 11883 Stockholm, Sweden
| | - Marcin Liro
- Department of Gynecology, Gynecologic Oncology and Gynecologic Endocrinology, Medical University, 80210 Gdańsk, Poland
| | - Alexandra Sufliarska
- Gynecologic Oncology Centre, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University, General University Hospital in Prague, 12851 Prague, Czech Republic
| | - Sebastian Szubert
- Clinical Department of Gynecological Oncology, The Franciszek Lukaszczyk Oncological Center, 85796 Bydgoszcz, Poland
- 2nd Department of Obstetrics and Gynecology, Centre of Postgraduate Medical Education, 01809 Warsaw, Poland
| | - Stefano Guerriero
- Department of Obstetrics and Gynecology, University of Cagliari, Policlinico Universitario Duilio Casula, Monserrato, 09124 Cagliari, Italy
| | - Elena Ioana Braicu
- Department of Gynecology, Campus Virchow, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany
| | - Mariusz Szajewski
- Department of Oncological Surgery, Gdynia Oncology Centre, 81519 Gdynia, Poland
- Division of Propedeutics of Oncology, Medical University of Gdańsk, 80210 Gdańsk, Poland
| | | | - Daniela Fischerova
- Gynecologic Oncology Centre, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University, General University Hospital in Prague, 12851 Prague, Czech Republic
| |
Collapse
|
8
|
Ciesielski M, Kruszewski WJ, Szajewski M, Walczak J, Spychalska N, Szefel J, Zieliński J. Extremely High Mortality Rate after a Successful Gastrectomy for Cancer in Older Adults. J Gastric Cancer 2019; 19:202-211. [PMID: 31245165 PMCID: PMC6589425 DOI: 10.5230/jgc.2019.19.e16] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 02/27/2019] [Accepted: 04/19/2019] [Indexed: 12/22/2022] Open
Abstract
PURPOSE Poor physiological reserve for withstanding major cancer surgery in older adults is an important concern in the selection of patients for oncologic gastrectomy. The present study aimed to analyze mortality patterns among patients who underwent gastrectomy for cancer according to age groups. The primary outcomes of this study were early- and middle-term results: 30-day and 3-, 6-, 12-, and 36-month mortality rates. MATERIALS AND METHODS A retrospective review of 288 patients who underwent surgical resection for gastric cancer in two centers was carried out. Patients were stratified into four groups according to age: 29-50 years (group I, n=27), 51-65 years (group II, n=117), 66-75 years (group III, n=81), and 76-92 years (group IV, n=58). Statistical calculations focused on the differences in the survival rates between groups I and II as well as between groups II and IV. RESULTS The middle-aged patients (group II) had significantly better 3-year survival than either the youngest (group I) or the oldest patients (group IV). The 6-month mortality rates were 16.9% in group III and 29.3% in group IV. Two-thirds of the patients from groups III and IV who died between 2 and 6 months after surgery had an uneventful postoperative course. CONCLUSIONS Age is an important prognostic factor of middle-term survival after gastrectomy for cancer. Geriatric assessment and better patient selection for major surgery for cancer are required to improve the outcome of gastrectomy for cancer in patients aged over 75 years.
Collapse
Affiliation(s)
- Maciej Ciesielski
- Department of Oncological Surgery, Gdynia Oncology Centre, Pomeranian Hospitals, Gdynia, Poland
- Division of Propedeutics of Oncology, Medical University of Gdańsk, Gdańsk, Poland
| | - Wiesław Janusz Kruszewski
- Department of Oncological Surgery, Gdynia Oncology Centre, Pomeranian Hospitals, Gdynia, Poland
- Division of Propedeutics of Oncology, Medical University of Gdańsk, Gdańsk, Poland
| | - Mariusz Szajewski
- Department of Oncological Surgery, Gdynia Oncology Centre, Pomeranian Hospitals, Gdynia, Poland
- Division of Propedeutics of Oncology, Medical University of Gdańsk, Gdańsk, Poland
| | - Jakub Walczak
- Department of Oncological Surgery, Gdynia Oncology Centre, Pomeranian Hospitals, Gdynia, Poland
| | - Natalia Spychalska
- Department of Oncological Surgery, Gdynia Oncology Centre, Pomeranian Hospitals, Gdynia, Poland
| | - Jarosław Szefel
- Department of Oncological Surgery, Gdynia Oncology Centre, Pomeranian Hospitals, Gdynia, Poland
- Division of Propedeutics of Oncology, Medical University of Gdańsk, Gdańsk, Poland
| | - Jacek Zieliński
- Department of Oncological Surgery, Medical University of Gdańsk, Gdańsk, Poland
| |
Collapse
|
9
|
Ciesielski M, Lewandowska M, Szajewski M, Walczak J, Pęksa R, Zieliński J, Lenckowski R, Supeł M, Kruszewski W. Impact of chromosome 17 polysomy on HER2 receptor overexpression and patients survival in gastric adenocarcinoma. Is HER2/CEP17 ratio an appropriate method of FISH assessment? Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
10
|
Ciesielski M, Szajewski M, Pęksa R, Lewandowska MA, Zieliński J, Walczak J, Szefel J, Kruszewski WJ. The relationship between HER2 overexpression and angiogenesis in gastric cancer. Medicine (Baltimore) 2018; 97:e12854. [PMID: 30334990 PMCID: PMC6211927 DOI: 10.1097/md.0000000000012854] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
In gastric cancer, HER2 protein overexpression is considered to be conducive to the higher proliferation activity of the tumor cells. Tumor formation is associated with angiogenesis in order to secure an abundant supply of oxygen and glucose to cancer cells. The aim of the study was to assess if HER2 overexpression is related to higher microvessel density (MVD) in the tumor stroma.The archival samples of primary tumor from 144 consecutive patients that underwent gastric resection for cancer between August 1, 2006 and December 31, 2013 in the Department of Oncological Surgery of Medical University of Gdańsk were analyzed. CD34 was used as a marker of MVD in the tumor stroma. Both CD34 and HER2 protein expressions were tested by immunohistochemistry.The assays were unsuccessful to estimate HER2 in 10 cases and CD34 in 14 cases due to technical reasons. The results were obtained for 128 patients. HER2 0 and HER2 1+ were considered negative, while HER2+ and HER2 3+ were recognized as positive. Mean MVD (mean number of vessels in the visual field) was 32.4 (median 29.5). Microvessel density was insignificantly higher in HER2 positive tumors. The slight difference was also seen between IHC 2+ and 3+ groups. The differences did not reach the level of statistical significance.Statistical analysis performed in our study did not reveal the significant relationship between HER2 overexpression on the tumor cells and MVD in the tumor stroma.
Collapse
Affiliation(s)
- Maciej Ciesielski
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia
- Division of Propedeutics of Oncology, Medical University Of Gdańsk
| | - Mariusz Szajewski
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia
- Division of Propedeutics of Oncology, Medical University Of Gdańsk
| | - Rafał Pęksa
- Department of Pathomorphology, Medical University of Gdańsk, Gdańsk
| | | | - Jacek Zieliński
- Department of Oncological Surgery, Medical University of Gdańsk, Gdańsk, Poland
| | - Jakub Walczak
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia
| | - Jarosław Szefel
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia
- Division of Propedeutics of Oncology, Medical University Of Gdańsk
| | - Wiesław Janusz Kruszewski
- Department of Oncological Surgery, Gdynia Oncology Centre, Gdynia
- Division of Propedeutics of Oncology, Medical University Of Gdańsk
| |
Collapse
|
11
|
Stukan M, Zalewski K, Mardas M, Filarska D, Szajewski M, Kmieć A, Bińkowska P, Pietrzak-Stukan M, Dudziak M, Grabowski JP, Eskander RN, Greimel E. Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). Eur J Cancer Care (Engl) 2017; 27. [PMID: 28058740 DOI: 10.1111/ecc.12639] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/01/2016] [Indexed: 12/19/2022]
Abstract
The endometrial cancer (EC)-specific Quality of Life module of the European Organization for Research and Treatment of Cancer (EORTC QLQ-EN24), was developed and validated in one study. We independently validated and assessed the psychometric properties of the instrument. Two hundred and eight women with EC before surgery, during adjuvant treatment and follow-up; in three different cancer centres completed the EORTC QLQ-C30 and the EN24. The questionnaire's completion rate was 100%, except sexuality items, that were answered by 35% of patients. All item-scale correlations for the multi-item scales exceeded the .4 criterion and correlated well with their own scale, while correlations with the other scales were low. The internal consistency of all multi-item scales were satisfactory (Cronbach's alpha coefficients ranging from .77 to .97). Discriminance for single-item scales was low. The QLQ-EN24 module discriminated well between clinically different patients, and there were no differences in quality of life questionnaire scales between patients with body mass index ≤30 when compared to those with >30. This validation study supports the reliability, as well as convergent and divergent validity of the EORTC QLQ-EN24. The module is a useful instrument for the assessment of QOL in patients with EC. However, data concerning sexuality should be interpreted with caution.
Collapse
Affiliation(s)
- M Stukan
- Department of Gynaecologic Oncology, Gdynia Oncology Centre, Gdynia, Poland.,Medicover Outpatient Clinic, Gdańsk, Poland
| | - K Zalewski
- Department of Clinical Oncology, Holycross Cancer Centre, Kielce, Poland.,Clinical Department of Obstetrics, Female Diseases and Gynaecological Oncology, II Medical Faculty, Medical University of Warsaw, Warsaw, Poland
| | - M Mardas
- Department of Human Nutrition and Hygiene, Poznan University of Life Sciences, Poznan, Poland
| | - D Filarska
- Department of Radiotherapy, Gdynia Oncology Centre, Gdynia, Poland
| | - M Szajewski
- Department of Propaedeutics of Oncology, Faculty of Health Sciences, Medical University of Gdańsk, Gdańsk, Poland.,Department of Surgical Oncology, Gdynia Oncology Centre, Gdynia, Poland
| | - A Kmieć
- Department of Gynaecologic Oncology, Gdynia Oncology Centre, Gdynia, Poland
| | - P Bińkowska
- Department of Medical Oncology, Gdynia Oncology Centre, Gdynia, Poland
| | | | - M Dudziak
- Department of Gynaecologic Oncology, Gdynia Oncology Centre, Gdynia, Poland
| | - J P Grabowski
- Department of Gynaecology, Charite-University of Medicine, Berlin, Germany
| | - R N Eskander
- Department of Obstetrics & Gynaecology, University of California Irvine Medical Centre, Orange, CA, USA
| | - E Greimel
- Department of Obstetrics and Gynaecology, Medical University of Graz, Graz, Austria
| |
Collapse
|
12
|
Zygoń J, Szajewski M, Kruszewski WJ, Rzepko R. VEGF, Flt-1, and microvessel density in primary tumors as predictive factors of colorectal cancer prognosis. Mol Clin Oncol 2016; 6:243-248. [PMID: 28357103 DOI: 10.3892/mco.2016.1121] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Accepted: 11/23/2016] [Indexed: 01/13/2023] Open
Abstract
Angiogenesis in the primary tumor is known to be necessary for tumor progression in adenocarcinomas of the colon. However, whether angiogenesis in the primary tumors of patients with colorectal cancer affects their prognosis has yet to be fully elucidated. The aim of the present study was to assess the association between selected pathoclinical parameters and overall survival of resectable colorectal cancer patients with the expression of angiogenesis-promoting factors, including vascular endothelial growth factor (VEGF) and Fms-like tyrosine kinase receptor (Flt-1), and microvessel density (MVD) in the primary tumor. VEGF and Flt-1 expression were assessed, as well as MVD (with anti-CD34) by immunohistochemistry in 139 archived primary colorectal cancer tissue samples. These results were compared with the overall survival of the patients and potential prognostic pathoclinical parameters. A higher MVD in the tumors expressing Flt-1 (P=0.04) was identified. However, there was no correlation between the pathoclinical parameters of colon cancer and Flt-1 expression, VEGF expression, or MVD in the tumor. Furthermore, the intensity of VEGF expression, Flt-1 expression and tumor MVD did not correlate with the overall survival of the patients. Therefore, although increased expression of VEGF and Flt-1 was correlated with an increased expression of MVD in the primary tumors of resectable colorectal cancer patients, these factors were not correlated with prognostic pathoclinical factors and overall survival.
Collapse
Affiliation(s)
- Justyna Zygoń
- Department of General Surgery, Kościerzyna Hospital Ltd., Kościerzyna 83-400, Poland
| | - Mariusz Szajewski
- Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital in Gdynia, Gdynia 81-519, Poland; Department of Propaedeutic of Oncology, Faculty of Health Sciences, Medical University of Gdańsk, Gdynia 81-519, Poland
| | - Wiesław Janusz Kruszewski
- Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital in Gdynia, Gdynia 81-519, Poland; Department of Propaedeutic of Oncology, Faculty of Health Sciences, Medical University of Gdańsk, Gdynia 81-519, Poland
| | - Robert Rzepko
- Department of Pathology, Prabuty Hospital Ltd., Prabuty 82-550, Poland
| |
Collapse
|
13
|
Ciesielski M, Szajewski M, Kruszewski W, Pęksa R, Zieliński J, Walczak J, Spychalska N. 616. The relation between HER2 overexpression on the tumour cells and microvessels density in the tumour stroma in gastric cancer. Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.06.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
14
|
Szutowicz-Wydra B, Wydra J, Kruszewski WJ, Ciesielski M, Szajewski M, Walczak J, Hansdorfer-Korzon R. Same Quality of Life for Polish Breast Cancer Patients Treated with Mastectomy and Breast Reconstruction or Breast-Conserving Therapy. Polish Journal of Surgery 2016; 88:264-269. [PMID: 27811351 DOI: 10.1515/pjs-2016-0062] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Indexed: 11/15/2022]
Abstract
AbstractBreast cancer often requires combined oncologic treatments, the base of which is surgery. Quality of life (QoL) after each surgical procedure may influence the process of decision making among women, who qualify for multiple oncological strategies. Our knowledge about QoL in breast cancer patients is derived from comparative studies. Results may differ, depending on country, culture, and societal relations.was to investigate the quality of life of Polish patients treated with breast-conserving therapy (BCT) or mastectomy with breast reconstruction.The study involved women who underwent surgery for breast cancer in the Department of Surgical Oncology of the Gdynia Oncology Center from September 2010 to November 2013. Eighty-two breast reconstructions (in 79 patients) and 226 BCT procedures were performed. QoL was measured with the use of EORTC QLQ-C30 and QLQ-BR23 questionnaires.Global QoL was high in both groups and did not differ significantly. Body image was slightly better after BCT than after mastectomy with breast reconstruction, but sexual QoL was lower. Future perspective was quite low in both groups. Disease symptoms were not bothering.The global QoL among Polish breast cancer patients treated with BCT or mastectomy with breast reconstruction is high and does not differ between groups. There is a need for anxiety and disease-related fear prophylaxis and for the improvement of sex life of breast cancer survivors.
Collapse
|
15
|
Szajewski M, Kruszewski WJ, Ciesielski M, Smiałek-Kusowska U, Czerepko M, Szefel J. Primary osteosarcoma of the breast: A case report. Oncol Lett 2014; 7:1962-1964. [PMID: 24932269 PMCID: PMC4049759 DOI: 10.3892/ol.2014.1981] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2013] [Accepted: 02/26/2014] [Indexed: 12/03/2022] Open
Abstract
Osteosarcoma (OS) located in the breast is an extremely rare, malignant neoplasm. The current study presents the diagnostic process, treatment and follow-up of a 67-year-old female with OS of the breast. The diagnosis was made according to diagnostic imaging methods and microscopic examination with additional immunohistochemical staining. As a surgical treatment, tumourectomy with intraoperative histological examination and simple breast amputation was performed. No adjuvant chemotherapy was administered following surgery. Lung and bone metastases occurred without local recurrence 14 months following the surgery. In the present study, the details of the diagnostic examinations performed are evaluated and the consecutive phases of diagnostic and therapeutic proceedings are examined in comparison with the knowledge in the literature.
Collapse
Affiliation(s)
- Mariusz Szajewski
- Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital in Gdynia, 81-519 Gdynia, Poland ; Department of Propedeutics of Oncology, Faculty of Health Sciences, Medical University of Gdańsk, 81-519 Gdynia, Poland
| | - Wiesław Janusz Kruszewski
- Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital in Gdynia, 81-519 Gdynia, Poland ; Department of Propedeutics of Oncology, Faculty of Health Sciences, Medical University of Gdańsk, 81-519 Gdynia, Poland
| | - Maciej Ciesielski
- Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital in Gdynia, 81-519 Gdynia, Poland ; Department of Propedeutics of Oncology, Faculty of Health Sciences, Medical University of Gdańsk, 81-519 Gdynia, Poland
| | | | - Maksymilian Czerepko
- Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital in Gdynia, 81-519 Gdynia, Poland
| | - Jarosław Szefel
- Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital in Gdynia, 81-519 Gdynia, Poland ; Department of Propedeutics of Oncology, Faculty of Health Sciences, Medical University of Gdańsk, 81-519 Gdynia, Poland
| |
Collapse
|
16
|
Szajewski M, Kruszewski WJ, Lakomy J, Ciesielski M, Kawecki K, Jankun J, Buczek T, Szefel J. VEGF-C and VEGF-D overexpression is more common in left-sided and well-differentiated colon adenocarcinoma. Oncol Rep 2013; 31:125-30. [PMID: 24173916 DOI: 10.3892/or.2013.2821] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2013] [Accepted: 10/08/2013] [Indexed: 11/05/2022] Open
Abstract
Tumour vessel network formation, including blood and lymph vessels, is a major step involved in the process of carcinogenesis. The discovery of vascular growth factors has led to a better understanding of tumour biology, thus, creating new possibilities for cancer treatment that targets angiogenesis within tumour-associated stroma, including therapy for colon cancer patients. The present study evaluated the relationships between increased expression of lymphangiogenic factors (VEGF-C and VEGF-D) and vessel density in the tumour-surrounding stroma, patient survival and other standard prognostic factors. The expression of VEGF-C and VEGF-D and vessel density were immunohistochemically assessed in 114 primary tumour specimens from colon adenocarcinoma patients after surgical resection between January 1, 2003 and December 31, 2008. Concomittant overexpression of VEGF-C and VEGF-D was found in 51 (44.7%) colon tumours and low expression was observed in 63 (55.3%) cases. Mean vessel density was 52.87/field. A significant correlation was found between the expression of factors influencing lymph vessel growth and increased vessel density in the tumour-surrounding stroma (p=0.03). A relationship between lymphangiogenic factor overexpression and left-sided tumour location was also found (p=0.00002). Overexpression of these factors was likely to occur in well-differentiated tumours (p=0.003). No association between patient survival and the expression levels of lymphangiogenic factors was observed. The study results indicate that the overexpression of lymphangiogenic factors tends to be associated with tumours of favourable prognosis, i.e. well-differentiated and those localized in the left-side of the colon.
Collapse
Affiliation(s)
- Mariusz Szajewski
- Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital in Gdynia, 81-519 Gdynia, Poland
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Kruszewski W, Wydra J, Jasinski W, Szajewski M, Ciesielski M, Szefel J, Walczak J. 367. Early Outcome of Surgical Treatment of Colorectal Cancer in Patients up to 75 Years and Older. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.06.344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
18
|
Kruszewski W, Ciesielski M, Szajewski M, Jasinski W, Szefel J, Kawecki K, Wydra J, Dilling P, Warezak C, Czerepko M. 88. Level of arterial ligation and early results of rectal cancer surgery – Preliminary report of randomized trial. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.06.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
19
|
Szefel J, Kruszewski WJ, Ciesielski M, Szajewski M, Kawecki K, Aleksandrowicz-Wrona E, Jankun J, Lysiak-Szydłowska W. L-carnitine and cancer cachexia. I. L-carnitine distribution and metabolic disorders in cancer cachexia. Oncol Rep 2012; 28:319-23. [PMID: 22562434 DOI: 10.3892/or.2012.1804] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2012] [Accepted: 04/18/2012] [Indexed: 12/29/2022] Open
Abstract
Cancer cachexia (CC), a progressive loss of body mass, is associated with decreased energy production. Abnormally low levels of L-carnitine (LC) in skeletal muscle means that mitochondrial β-oxidation of long-chain fatty acids (LCFA) does not occur efficiently in patients with CC. We assessed the influence of CC on LC distribution and the effects of parenteral lipid emulsions on plasma LC levels and urinary excretion. Fifty patients with CC were randomly assigned to total parenteral nutrition (TPN) with long-chain triglycerides (LCTs), or LCTs plus medium-chain triglycerides (MCTs) as 50/50. Patients were further separated into those with body-mass index (BMI) ≤ 19 kg/m(2) and BMI >19 kg/m(2). Plasma concentrations of total LC (TC) and free LC (FC) and their urinary excretion were measured, along with skeletal muscle LC levels. On average, plasma FC and TC were higher than reference values in all patients. Patients with BMI ≤ 19 kg/m(2) had lower plasma FC and TC than those with BMI >19 kg/m(2). Skeletal muscle FC in the BMI ≤ 19 kg/m(2) group was lower than reference value, but within the normal range in others. LC and FC urinary excretion was higher than reference values. Plasma LC and its urinary excretion were higher in patients administered pure LCTs relative to those given MCTs/LCTs. A decrease in skeletal muscle LC in cancer patients with CC (BMI ≤ 19 kg/m(2)) correlates with an increase in its plasma levels and increased renal excretion. A diet of MCTs/LCTs reduces LC release from muscle to plasma and urine more effectively than LCTs.
Collapse
Affiliation(s)
- Jarosław Szefel
- Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital in Gdynia, Gdynia, Poland.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Szefel J, Kruszewski WJ, Ciesielski M, Szajewski M, Kawecki K, Jankun J, Lysiak-Szydłowska W. L-carnitine and cancer cachexia. II. Effects of lipid emulsion used in total parenteral nutrition on parameters of hemostasis and inflammatory state in L-carnitine deficiency in myocytes. Oncol Rep 2012; 28:324-9. [PMID: 22562458 DOI: 10.3892/or.2012.1805] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2012] [Accepted: 04/18/2012] [Indexed: 11/06/2022] Open
Abstract
Cancer cachexia (CC), a progressive loss of body mass, leads to malnutrition and deficiencies of essential substances including polyunsaturated fatty acids (PUFAs) and L-carnitine (LC). The availability of these 2 compounds determines the rate of eicosanoid synthesis, which modulates inflammatory processes and hemostasis. We compared the effects of administration of emulsions containing long chain triglycerides (LCTs) relative to a 50:50 mix of medium chain triglycerides (MCTs) with LCTs on hemostasis and inflammatory reactions in patients with CC. The study was conducted on 50 patients with CC (23 women, 27 men) aged 66 ± 11 years with a mean loss in body weight of 21 ± 9% in the previous 6 months. Twenty patients received MCTs/LCTs while 30 received LCTs. Total parenteral nutrition (TPN) was administered using the 'all in one' method (25 kcal/kg/day, protein 1.2 g/kg/day). Selected parameters of coagulation and inflammatory state were evaluated on days 1, 5, 7 and 11 of TPN. Initial concentrations of D-dimers, fibrinogen, plasminogen activator inhibitor type 1 (PAI-1), fibronectin, CRP and IL-6 significantly exceeded the upper limit of the reference values. After 10 days of TPN, we detected significant differences in inflammatory state and hemostasis. Immunological state and hemostasis varied depending on the type of fat emulsion administered. The most likely reasons are the 2-fold higher concentrations of PUFAs in LCTs relative to MCTs/LCTs and a deficiency of LC in skeletal muscles. Both of these factors may contribute to the observed increase in the rate of eicosanoid synthesis.
Collapse
Affiliation(s)
- Jarosław Szefel
- Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital, Gdynia, Poland.
| | | | | | | | | | | | | |
Collapse
|
21
|
Kruszewski WJ, Rzepko R, Ciesielski M, Szefel J, Zieliński J, Szajewski M, Jasiński W, Kawecki K, Wojtacki J. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers 2011; 29:207-12. [PMID: 21206005 PMCID: PMC3835377 DOI: 10.3233/dma-2010-0742] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Estimation of HER2 membranous expression is routinely used in breast and gastric cancers, as both a prognostic and a predictive factor. To date there is no evidence for similar application of HER2 expression in colorectal cancer (CRC) cells. In CRC, HER2 is sometimes overexpressed in the cell membrane and very often in the cytoplasm. This study was conducted to determine possible correlations between both membranous and cytoplasmatic expression of HER2 in CRC cells and the outcome of the disease. The prognostic significance of combined staining intensity in the cell membrane and cytoplasm in the entire CRC cell was also investigated. HER2 expression in resectable colorectal adenocarcinoma cells was evaluated by immunohistochemistry in specimens taken from 202 patients. The percentage of cancer cells with membranous or cytoplasmatic reactions and the staining intensity of the reaction in the whole cell were recorded. A membranous reaction was present in 27% of cases, and cytoplasmatic reaction in 66% of cases. The total staining intensity in the entire cell was evaluated as moderate (2+) in 32% of cases and strong (3+) staining in 15%. There was no correlation found between either membranous or cytoplasmatic HER2 expression and survival. Furthermore combined staining intensity did not provide any prognostic information. We conclude that HER2 expression in CRC does not correlate with prognosis.
Collapse
|
22
|
Szajewski M, Kruszewski WJ, Ciesielski M, Pikiel P. [Surgical treatment of megacolon--case report]. Przegl Lek 2008; 65:408-409. [PMID: 19140391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Megacolon is a state of pathological extension of the large bowel. In this paper diagnostic process and both: conservative and operative treatment of 76 years old female patient suffering from megacolon were described. The main causes of the disease were probably in this patient: chronic constipation, diabetes, and cardiovascular problems. In summary, methods of treatment of different forms of megacolon were discussed.
Collapse
Affiliation(s)
- Mariusz Szajewski
- Oddzial Chirurgii Onkologicznej, Gdyńskie Centrum Onkologii, Szpital Morski w Gdyni.
| | | | | | | |
Collapse
|